DNA methylation pattern of the SLC25A43 gene in breast cancer

Epigenetics

Volumn 7, Issue 3, 2012, Pages 300-306

  Lindqvist, Breezy Malakkaran ^a   Farkas, Sanja A ^b   Wingren, Sten ^a   Nilsson, Torbjörn K ^a,b  

^a ÖREBRO UNIVERSITY   (Sweden)

^b ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Breast cancer; CpG island; CpG shore; Gene inactivation; HER2 receptor; Methylation; SLC25A43 gene

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN; SOLUTE CARRIER FAMILY 25A MEMBER 43; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ADULT; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER TISSUE; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; FEMALE; GENE DELETION; GENE INACTIVATION; GENE MUTATION; GENE SILENCING; GENETIC CODE; HEALTH STATUS; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; LYMPH NODE; PROTEIN ANALYSIS; PYROSEQUENCING;

EID: 84858205498     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.7.3.19064     Document Type: Article

References (50)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127:2893-917; PMID:21351269; http://dx.doi.org/10.1002/ijc.25516.
2. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98:10869-74; PMID:11553815; http://dx.doi.org/10.1073/pnas.191367098.
3. Schmitt F. HER2+ breast cancer: how to evaluate? Adv Ther 2009; 26:1-8; PMID:19669636; http://dx.doi.org/10.1007/s12325-009-0046-1.
4. Carey LA. Through a glass darkly: advances in understanding breast cancer biology, 2000-10. Clin Breast Cancer 2010; 10:188-95; PMID:20497917; http://dx.doi.org/10.3816/CBC.2010.n.026.
5. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-92; PMID:11248153; http://dx.doi.org/10.1056/NEJM200103153441101.
6. Esteva FJ. The current status of docetaxel for metastatic breast cancer. [Williston Park]. Oncology (Williston Park) 2002; 16:17-26; PMID:12108894.
7. Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer 2004; 11:643-58; PMID:15613444; http://dx.doi.org/10.1677/erc.1.00776.
8. Jordan VC. Tamoxifen or raloxifene for breast cancer chemoprevention: a tale of two choices-point. Cancer Epidemiol Biomarkers Prev 2007; 16:2207-9; PMID:18006908; http://dx.doi.org/10.1158/1055-9965.EPI-07-0629.
9. Haitina T, Lindblom J, Renström T, Fredriksson R. Fourteen novel human members of mitochondrial solute carrier family 25 (SLC25) widely expressed in the central nervous system. Genomics 2006; 88:779-90; PMID:16949250; http://dx.doi.org/10.1016/j.ygeno.2006.06.016.
10. Palmieri F. The mitochondrial transporter family (SLC25): physiological and pathological implications. Pflugers Arch 2004; 447:689-709; PMID:14598172; http://dx.doi.org/10.1007/s00424-003-1099-7.
11. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 1998; 72:141-96; PMID:9338076; http://dx.doi.org/10.1016/S0065-230X(08)60702-2.
12. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet 1999; 21:163-7; PMID:9988266; http://dx.doi.org/10.1038/5947.
13. Bird AP. CpG-rich islands and the function of DNA methylation. Nature 1986; 321:209-13; PMID:2423876; http://dx.doi.org/10.1038/321209a0.
14. Ji H, Ehrlich LI, Seita J, Murakami P, Doi A, Lindau P, et al. Comprehensive methylome map of lineage commitment from haematopoietic progenitors. Nature 2010; 467:338-42; PMID:20720541; http://dx.doi.org/10.1038/nature09367.
15. Doi A, Park IH, Wen B, Murakami P, Aryee MJ, Irizarry R, et al. Differential methylation of tissueand cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat Genet 2009; 41:1350-3; PMID:19881528; http://dx.doi.org/10.1038/ng.471.
16. Milani L, Lundmark A, Nordlund J, Kiialainen A, Flaegstad T, Jonmundsson G, et al. Allele-specific gene expression patterns in primary leukemic cells reveal regulation of gene expression by CpG site methylation. Genome Res 2009; 19:1-11; PMID:18997001; http://dx.doi.org/10.1101/gr.083931.108.
17. Hellman A, Chess A. Gene body-specific methylation on the active X chromosome. Science 2007; 315:1141-3; PMID:17322062; http://dx.doi.org/10.1126/science.1136352.
18. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128:683-92; PMID:17320506; http://dx.doi.org/10.1016/j.cell.2007.01.029.
19. Portela A, Esteller M. Epigenetic modifications and human disease. Nat Biotechnol 2010; 28:1057-68; PMID:20944598; http://dx.doi.org/10.1038/nbt.1685.
20. Futscher BW, O'Meara MM, Kim CJ, Rennels MA, Lu D, Gruman LM, et al. Aberrant methylation of the maspin promoter is an early event in human breast cancer. Neoplasia 2004; 6:380-9; PMID:15256060; http://dx.doi.org/10.1593/neo.04115.
21. Bettstetter M, Woenckhaus M, Wild PJ, Rümmele P, Blaszyk H, Hartmann A, et al. Elevated nuclear maspin expression is associated with microsatellite instability and high tumour grade in colorectal cancer. J Pathol 2005; 205:606-14; PMID:15714592; http://dx.doi.org/10.1002/path.1732.
22. Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer 2003; 3:253-66; PMID:12671664; http://dx.doi.org/10.1038/nrc1045.
23. Greger V, Passarge E, Höpping W, Messmer E, Horsthemke B. Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma. Hum Genet 1989; 83:155-8; PMID:2550354; http://dx.doi.org/10.1007/BF00286709.
24. Sakai T, Toguchida J, Ohtani N, Yandell DW, Rapaport JM, Dryja TP. Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene. Am J Hum Genet 1991; 48:880-8; PMID:1673287.
25. Esteller M, Corn PG, Urena JM, Gabrielson E, Baylin SB, Herman JG. Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia. Cancer Res 1998; 58:4515-8; PMID:9788592.
26. Kane MF, Loda M, Gaida GM, Lipman J, Mishra R, Goldman H, et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 1997; 57:808-11; PMID:9041175.
27. Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 1998; 95:6870-5; PMID:9618505; http://dx.doi.org/10.1073/pnas.95.12.6870.
28. Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 1999; 59:67-70; PMID:9892187.
29. Lehmann U, Länger F, Feist H, Glöckner S, Hasemeier B, Kreipe H. Quantitative assessment of promoter hypermethylation during breast cancer development. Am J Pathol 2002; 160:605-12; PMID:11839581; http://dx.doi.org/10.1016/S0002-9440(10)64880-8.
30. Fackler MJ, McVeigh M, Evron E, Garrett E, Mehrotra J, Polyak K, et al. DNA methylation of RASSF1A, HIN-1, RARbeta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma. Int J Cancer 2003; 107:970-5; PMID:14601057; http://dx.doi.org/10.1002/ijc.11508.
31. Lee JS. GSTP1 promoter hypermethylation is an early event in breast carcinogenesis. Virchows Arch 2007; 450:637-42; PMID:17479284; http://dx.doi.org/10.1007/s00428-007-0421-8.
32. Subramaniam MM, Chan JY, Soong R, Ito K, Ito Y, Yeoh KG, et al. RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression. Breast Cancer Res Treat 2009; 113:113-21; PMID:18256927; http://dx.doi.org/10.1007/s10549-008-9917-4.
33. Lorincz MC, Dickerson DR, Schmitt M, Groudine M. Intragenic DNA methylation alters chromatin structure and elongation efficiency in mammalian cells. Nat Struct Mol Biol 2004; 11:1068-75; PMID:15467727; http://dx.doi.org/10.1038/nsmb840.
34. Lin CH, Hsieh SY, Sheen IS, Lee WC, Chen TC, Shyu WC, et al. Genome-wide hypomethylation in hepatocellular carcinogenesis. Cancer Res 2001; 61:4238-43; PMID:11358850.
35. Goelz SE, Vogelstein B, Hamilton SR, Feinberg AP. Hypomethylation of DNA from benign and malignant human colon neoplasms. Science 1985; 228:187-90; PMID:2579435; http://dx.doi.org/10.1126/science.2579435.
36. Gaudet F, Hodgson JG, Eden A, Jackson-Grusby L, Dausman J, Gray JW, et al. Induction of tumors in mice by genomic hypomethylation. Science 2003; 300:489-92; PMID:12702876; http://dx.doi.org/10.1126/science.1083558.
37. Schulz WA, Elo JP, Florl AR, Pennanen S, Santourlidis S, Engers R, et al. Genomewide DNA hypomethylation is associated with alterations on chromosome 8 in prostate carcinoma. Genes Chromosomes Cancer 2002; 35:58-65; PMID:12203790; http://dx.doi.org/10.1002/gcc.10092.
38. Jackson K, Yu MC, Arakawa K, Fiala E, Youn B, Fiegl H, et al. DNA hypomethylation is prevalent even in low-grade breast cancers. Cancer Biol Ther 2004; 3:1225-31; PMID:15539937; http://dx.doi.org/10.4161/cbt.3.12.1222.
39. Wilson AS, Power BE, Molloy PL. DNA hypomethylation and human diseases. Bio chim Bio phys Acta 2007; 1775:138-62.
40. Piotrowski A, Benetkiewicz M, Menzel U, Díaz de Ståhl T, Mantripragada K, Grigelionis G, et al. Microarraybased survey of CpG islands identifies concurrent hyper- and hypomethylation patterns in tissues derived from patients with breast cancer. Genes Chromosomes Cancer 2006; 45:656-67; PMID:16575877; http://dx.doi.org/10.1002/gcc.20331.
41. Chien J, Staub J, Avula R, Zhang H, Liu W, Hartmann LC, et al. Epigenetic silencing of TCEAL7 (Bex4) in ovarian cancer. Oncogene 2005; 24:5089-100; PMID:1587069; http://dx.doi.org/10.1038/sj.onc.1208700.
42. Dewdney SB, Rimel BJ, Thaker PH, Thompson DM Jr, Schmidt A, Huettner P, et al. Aberrant methylation of the X-linked ribosomal S6 kinase RPS6KA6 (RSK4) in endometrial cancers. Clin Cancer Res 2011; 17:2120-9; PMID:21372219; http://dx.doi.org/10.1158/1078-0432.CCR-10-2668.
43. Irizarry RA, Ladd-Acosta C, Wen B, Wu Z, Montano C, Onyango P, et al. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet 2009; 41:178-86; PMID:19151715; http://dx.doi.org/10.1038/ng.298.
44. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983; 301:89-92; PMID:6185846; http://dx.doi.org/10.1038/301089a0.
45. Strathdee G, Davies BR, Vass JK, Siddiqui N, Brown R. Cell type-specific methylation of an intronic-CpG island controls expression of the MCJ gene. Carcinogenesis 2004; 25:693-701; PMID:14729589; http://dx.doi.org/10.1093/carcin/bgh066.
46. Nguyen C, Liang G, Nguyen TT, Tsao-Wei D, Groshen S, Lübbert M, et al. Susceptibility of nonpromoterCpG islands to de novo methylation in normal and neoplastic cells. J Natl Cancer Inst 2001; 93:1465-72; PMID:11584062; http://dx.doi.org/10.1093/jnci/93.19.1465.
47. Cotton AM, Lam L, Affleck JG, Wilson IM, Peñaherrera MS, McFadden DE, et al. Chromosomewide DNA methylation analysis predicts human tissuespecific X inactivation. Hum Genet 2011; 130:187-201; PMID:21597963; http://dx.doi.org/10.1007/s00439-011-1007-8.
48. Tusnády GE, Simon I, Váradi A, Arányi T. BiSearch: primer-design and search tool for PCR on bisulfite-treated genomes. Nucleic Acids Res 2005; 33:9; PMID:15653630; http://dx.doi.org/10.1093/nar/gni012.
49. Löf-Öhlin ZM, Levanat S, Sabol M, Sorbe B, Nilsson TK. Promoter methylation in the PTCH gene in cervical epithelial cancer and ovarian cancer tissue as studied by eight novel Pyrosequencing® assays. Int J Oncol 2011; 38:685-92; PMID:21206974.
50. Goossens E, De Rycke M, Haentjens P, Tournaye H. DNA methylation patterns of spermatozoa and two generations of offspring obtained after murine spermatogonial stem cell transplantation. Hum Reprod 2009; 24:2255-63; PMID:19525299; http://dx.doi.org/10.1093/humrep/dep213.